- Home
- BWIN vs SANA Comparison
BWIN vs SANA Comparison
Compare BWIN & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BWIN | SANA |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BWIN | SANA |
|---|---|---|
| Price | $22.46 | $4.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $38.43 | $7.83 |
| AVG Volume (30 Days) | 1.2M | ★ 5.2M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,487,497,000.00 | N/A |
| Revenue This Year | $10.87 | N/A |
| Revenue Next Year | $10.97 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 10.69 | N/A |
| 52 Week Low | $21.26 | $1.26 |
| 52 Week High | $47.15 | $7.30 |
Technical Indicators
Market Signals| Indicator | BWIN | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 35.59 | 59.30 |
| Support Level | $21.78 | $4.25 |
| Resistance Level | $24.91 | $5.36 |
| Average True Range (ATR) | 1.57 | 0.52 |
| MACD | -0.36 | 0.11 |
| Stochastic Oscillator | 9.75 | 77.95 |
Price Performance
Historical ComparisonAbout BWIN The Baldwin Insurance Group Inc.
The Baldwin Insurance Group Inc is a United States-based insurance distribution firm. Its products include Business Insurance, Benefits Consulting, Reinsurance, Specialty MGA, Embedded Insurance., Personal insurance, etc.
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.